The ACE-2 in COVID-19: Foe or Friend?
Angiotensin-Converting Enzyme 2
Betacoronavirus
/ isolation & purification
COVID-19
Coronavirus Infections
/ physiopathology
Humans
Metabolic Diseases
/ physiopathology
Pandemics
Peptidyl-Dipeptidase A
/ genetics
Pneumonia, Viral
/ physiopathology
Prognosis
Renin-Angiotensin System
/ genetics
SARS-CoV-2
Journal
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
ISSN: 1439-4286
Titre abrégé: Horm Metab Res
Pays: Germany
ID NLM: 0177722
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
pubmed:
28
4
2020
medline:
16
5
2020
entrez:
28
4
2020
Statut:
ppublish
Résumé
COVID-19 is a rapidly spreading outbreak globally. Emerging evidence demonstrates that older individuals and people with underlying metabolic conditions of diabetes mellitus, hypertension, and hyperlipidemia are at higher risk of morbidity and mortality. The SARS-CoV-2 infects humans through the angiotensin converting enzyme (ACE-2) receptor. The ACE-2 receptor is a part of the dual system renin-angiotensin-system (RAS) consisting of ACE-Ang-II-AT
Identifiants
pubmed: 32340044
doi: 10.1055/a-1155-0501
pmc: PMC7339082
doi:
Substances chimiques
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-263Subventions
Organisme : MOH-CSAINV17nov-0006
ID : Ministry of Health, Clinician Scientist Award
Organisme : NMRC/CG/017/2013
ID : National Medical Research Council Centre Grant
Informations de copyright
© Georg Thieme Verlag KG Stuttgart · New York.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
AJR Am J Roentgenol. 2020 May;214(5):1078-1082
pubmed: 32108495
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Vasc Health Risk Manag. 2008;4(4):787-803
pubmed: 19065996
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014
pubmed: 32061198
Biochimie. 2017 Jun;137:132-138
pubmed: 28288872
JAMA. 2020 Feb 7;:
pubmed: 32031570
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):139-144
pubmed: 32057211
Horm Metab Res. 1998 Jan;30(1):12-5
pubmed: 9503033
J Card Fail. 2020 May;26(5):370
pubmed: 32439095
Aging Cell. 2020 Jun 19;:
pubmed: 32558150
J Korean Med Sci. 2020 Mar 16;35(10):e112
pubmed: 32174069
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Biochem Pharmacol. 2008 Feb 15;75(4):781-6
pubmed: 17897633
Hypertension. 2014 Dec;64(6):1368-1375
pubmed: 25225202
Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1140-E1149
pubmed: 31638856
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Crit Care. 2017 Sep 7;21(1):234
pubmed: 28877748
J Virol. 2005 Dec;79(23):14614-21
pubmed: 16282461
Mol Cell Endocrinol. 2013 Sep 25;378(1-2):15-22
pubmed: 22564510
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Int J Pept. 2012;2012:256294
pubmed: 22536270
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Biochem Biophys Res Commun. 2020 May 7;525(3):812-818
pubmed: 32169277
J Pathol. 2011 Dec;225(4):618-27
pubmed: 22009550
Br J Pharmacol. 2013 Jun;169(3):477-92
pubmed: 23488800
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Peptides. 2012 Apr;34(2):427-32
pubmed: 22391260
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Am J Respir Crit Care Med. 2015 Aug 1;192(3):315-23
pubmed: 25945397
Nat Rev Endocrinol. 2020 Jun;16(6):297-298
pubmed: 32242089
J Thorac Oncol. 2020 May;15(5):700-704
pubmed: 32114094
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651